Vertex Pharmaceuticals (VRTX) Stock Drops on Rumors September 14, 2016 - Baystreet.ca Written by Ophir Gottlieb PREFACE Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are plummeting today on rumors that the company is seeing an unexpected slowing of prescription refills during July and August according to a tweet sent out from Benzinga Pro. STORY Vertex Pharmaceuticals Incorporated had seen a nice run up in stock price from lows made in March, as the stock rose from just below $76 to $103 in just six months. Today, however, although the news has not been confirmed as of yet, it appears that run has come to an end. The Benzinga Pro tweet is one of several sources noting that the company has seen an unexpected slowdown in sales and the stock price has dropped nearly 6% in an abrupt intraday day move. In a tweet sent out by Twitter verified account @adamfeuerstein, we also got this news: $VRTX -6% on management walking back expectations for Orkambi Q3 sales. Orkambi refills lagged over summer. As of 9:55am PST, this is how the one minute intraday stock chart looks: Note that this rumor surfaced well after the market's open. WHY THIS MATTERS The opportunity that so many investors say they seek out, that they desire, is to find the technology companies that are powering the various coming revolutions in the "third wave" of technology. It's identifying trends and companies like this this that allows us to find the 'next Apple' or the 'next Google.' This is what CML Pro does. Our research sits side-by-side with Goldman Sachs, Morgan Stanley and the rest on professional terminals, but we are the anti-institution and break the information advantage the top .1% have. Each company in our 'Top Picks' is the single winner in an exploding thematic shift like artificial intelligence, Internet of Things, drones, biotech and more. For a limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.
Vertex Pharmaceuticals (VRTX) Stock Drops on Rumors September 14, 2016 - Baystreet.ca Written by Ophir Gottlieb PREFACE Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares are plummeting today on rumors that the company is seeing an unexpected slowing of prescription refills during July and August according to a tweet sent out from Benzinga Pro. STORY Vertex Pharmaceuticals Incorporated had seen a nice run up in stock price from lows made in March, as the stock rose from just below $76 to $103 in just six months. Today, however, although the news has not been confirmed as of yet, it appears that run has come to an end. The Benzinga Pro tweet is one of several sources noting that the company has seen an unexpected slowdown in sales and the stock price has dropped nearly 6% in an abrupt intraday day move. In a tweet sent out by Twitter verified account @adamfeuerstein, we also got this news: $VRTX -6% on management walking back expectations for Orkambi Q3 sales. Orkambi refills lagged over summer. As of 9:55am PST, this is how the one minute intraday stock chart looks: Note that this rumor surfaced well after the market's open. WHY THIS MATTERS The opportunity that so many investors say they seek out, that they desire, is to find the technology companies that are powering the various coming revolutions in the "third wave" of technology. It's identifying trends and companies like this this that allows us to find the 'next Apple' or the 'next Google.' This is what CML Pro does. Our research sits side-by-side with Goldman Sachs, Morgan Stanley and the rest on professional terminals, but we are the anti-institution and break the information advantage the top .1% have. Each company in our 'Top Picks' is the single winner in an exploding thematic shift like artificial intelligence, Internet of Things, drones, biotech and more. For a limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.